EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

TEAD Inhibitors Sensitize KRASG12C Inhibitors via Dual Cell Cycle Arrest in KRASG12C-Mutant NSCLC

Salvina Laura Tammaccaro, Philippe Prigent, Jean-Christophe Le Bail, Odette Dos-Santos, Laurent Dassencourt, Myriam Eskandar, Armelle Buzy, Olivier Venier, Jean-Claude Guillemot, Yaligara Veeranagouda, Michel Didier, Emmanuel Spanakis und 12 weitere

Pharmaceuticals · 06.04.2023 · 16 (4) · 553

DOI: 10.3390/ph16040553 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmaceuticals, online erschienen am 06.04.2023. Verfasst von Salvina Laura Tammaccaro und 23 weiteren Autor:innen. Beteiligte Einrichtung: Oncology, Sanofi R&D, 94400 Vitry-sur-Seine, France. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Sanofi (France).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

KRASG12C is one of the most common mutations detected in non-small cell lung cancer (NSCLC) patients, and it is a marker of poor prognosis. The first FDA-approved KRASG12C inhibitors, sotorasib and adagrasib, have been an enormous breakthrough for patients with KRASG12C mutant NSCLC; however, resistance to therapy is emerging. The transcriptional coactivators YAP1/TAZ and the family of transcription factors TEAD1-4 are the downstream effectors of the Hippo pathway and regulate essential cellular processes such as cell proliferation and cell survival. YAP1/TAZ-TEAD activity has further been implicated as a mechanism of resistance to targeted therapies. Here, we investigate the effect of combining TEAD inhibitors with KRASG12C inhibitors in KRASG12C mutant NSCLC tumor models. We show that TEAD inhibitors, while being inactive as single agents in KRASG12C-driven NSCLC cells, enhance KRASG12C inhibitor-mediated anti-tumor efficacy in vitro and in vivo. Mechanistically, the dual inhibition of KRASG12C and TEAD results in the downregulation of MYC and E2F signatures and in the alteration of the G2/M checkpoint, converging in an increase in G1 and a decrease in G2/M cell cycle phases. Our data suggest that the co-inhibition of KRASG12C and TEAD leads to a specific dual cell cycle arrest in KRASG12C NSCLC cells.

Schlagwörter

Stichwörter der Autor:innen

KRASG12CNSCLCYAP1-TEADcell cycle arrestresistance

Autor:innen und Institutionen

  • Oncology, Sanofi R&D, 94400 Vitry-sur-Seine, France.
  • Bio Structure and Biophysics, Sanofi R&D, 94400 Vitry-sur-Seine, France.
  • Small Molecules Medicinal Chemistry, Sanofi R&D, 91380 Chilly-Mazarin, France.
  • Genomics and Proteomics, Translational Sciences, Sanofi R&D, 91380 Chilly-Mazarin, France.
  • Precision Oncology, Sanofi R&D, 94400 Vitry-sur-Seine, France.
  • Molecular & Digital Histopathology, Sanofi R&D, 94400 Vitry-sur-Seine, France.

Förderung

  • Sanofi (France)

Zitieren

APA

Tammaccaro, S. L., Prigent, P., Le Bail, J. C., Dos-Santos, O., Dassencourt, L., Eskandar, M., Buzy, A., Venier, O., Guillemot, J. C., Veeranagouda, Y., Didier, M., Spanakis, E., Kanno, T., Cesaroni, M., Mathieu, S., Canard, L., Casse, A., Windenberger, F., Calvet, L., …, & Valtingojer, I. (2023). TEAD Inhibitors Sensitize KRASG12C Inhibitors via Dual Cell Cycle Arrest in KRASG12C-Mutant NSCLC. Pharmaceuticals, 16(4), 553. https://doi.org/10.3390/ph16040553

Vancouver

Tammaccaro SL, Prigent P, Le Bail JC, Dos-Santos O, Dassencourt L, Eskandar M, et al. TEAD Inhibitors Sensitize KRASG12C Inhibitors via Dual Cell Cycle Arrest in KRASG12C-Mutant NSCLC. Pharmaceuticals. 2023;16(4):553. doi:10.3390/ph16040553

BibTeX
@article{Tammaccaro2023,
  author = {Tammaccaro, Salvina Laura and Prigent, Philippe and Le Bail, Jean-Christophe and Dos-Santos, Odette and Dassencourt, Laurent and Eskandar, Myriam and Buzy, Armelle and Venier, Olivier and Guillemot, Jean-Claude and Veeranagouda, Yaligara and Didier, Michel and Spanakis, Emmanuel and Kanno, Tokuwa and Cesaroni, Matteo and Mathieu, Stephane and Canard, Luc and Casse, Alhassan and Windenberger, Fanny and Calvet, Loreley and Noblet, Laurence and Sidhu, Sukhvinder and Debussche, Laurent and Moll, Jurgen and Valtingojer, Iris},
  title = {TEAD Inhibitors Sensitize KRASG12C Inhibitors via Dual Cell Cycle Arrest in KRASG12C-Mutant NSCLC},
  journal = {Pharmaceuticals},
  year = {2023},
  volume = {16},
  number = {4},
  pages = {553},
  doi = {10.3390/ph16040553}
}
Kostenlos starten →